Difference between revisions of "Team:EPFL"

 
(53 intermediate revisions by 5 users not shown)
Line 1: Line 1:
{{EPFL/Head}}
+
{{EPFL/Header}}
 
<html>
 
<html>
  
 
<body>
 
<body>
  
   <div class="container-fluid bg-1 text-center">
+
   <main>
    <h1>CAPOEIRA</h1>
+
    <img src="https://static.igem.org/mediawiki/2018/3/3e/T--EPFL--encapsulin.jpg" class="img-circle" alt="encapsulin" width="150" height="150">
+
    <h3>Cancer Personalized Encapsulin Immunotherapy and Relapse Assay</h3>
+
  </div>
+
  
  <div class="container bg-2 text-center">
 
    <br>
 
    <a href="https://2018.igem.org/Team:EPFL/Description"><strong>What is CAPOEIRA ?</strong></a>
 
    <hr>
 
    <p style="font-size:20px;">While cancer is still the disease of the 21st century, new insights and approaches are changing the landscape of cancer therapy. Cancer immunotherapy is becoming a key technique for the successful fight against cancer. The goal of cancer immunotherapy
 
      is to harness the immune system in the fight against cancer. The project that the EPFL 2018 iGEM team is presenting is focused on the development of a new therapeutic approach to target specific types of cancer using immunotherapy methods, with
 
      a focus on vaccines. Furthermore, the project aims to integrate the personalized medicine approaches, by using patient-specific neoantigens to trigger the immune system and produce the response against cancer. The project is exhaustive and can be
 
      divided into the following parts:</p>
 
    <br>
 
  </div>
 
  
  
  <div class="container-fluid text-center">
+
 
    <div class="col-sm-3">
+
    <!-- Spotlight -->
      <a href="https://2018.igem.org/Team:EPFL/Description#Detection">
+
    <section class="slice slice-xl bg-dark">
      <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--Detection.png" class="img-circle project_part" alt="detection" width="255" height="255"> <br>
+
      <div class="container">
     </a>
+
        <div class="row row-grid align-items-center">
       <p><strong>Detection of cancer patient specific tumor mutations and neoantigens</strong></p>
+
          <div class="col-lg-5">
 +
            <div class="pt-lg-lg pb-lg-sm text-center text-lg-left">
 +
              <h2 class="h1 text-white mb-3">CAPOEIRA</h2>
 +
              <p class="lead text-white lh-180">CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay</p>
 +
 
 +
                          <a href="https://2018.igem.org/Team:EPFL/Description" class="btn btn-white btn-circle btn-translate--hover btn-icon mr-sm-4 scroll-me">
 +
 
 +
                                      <span class="btn-inner--text">Learn more about our project</span>
 +
                                      <span class="btn-inner--icon"><i class="fas fa-angle-right"></i></span>
 +
                                  </a>
 +
            </div>
 +
          </div>
 +
          <div class="col-lg-6 ml-lg-auto text-center">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b0/T--EPFL--LOGO_INVERT.png" style="width: 300px;">
 +
          </div>
 +
        </div>
 +
      </div>
 +
      <div class="shape-container" data-shape-style="curve" data-shape-position="bottom">
 +
        <svg class="shape-fill-primary" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 1000 100" preserveAspectRatio="none">
 +
                <path d="M 0 0 c 0 0 200 50 500 50 s 500 -50 500 -50 v 101 h -1000 v -100 z"></path>
 +
            </svg>
 +
      </div>
 +
     </section>
 +
 
 +
 
 +
 
 +
 
 +
 
 +
    <section class="slice slice-xl bg-primary" id="CAP">
 +
      <div class="container">
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-12">
 +
            <div class="pr-md-4">
 +
              <h3 class="heading h3 text-white text-center"><font size="+2">What is CAPOEIRA ?</font></h2>
 +
              <p class="lead text-white my-4">While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project
 +
                “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance.
 +
                First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments
 +
                presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential
 +
                relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!
 +
 
 +
              </p>
 +
            </div>
 +
          </div>
 +
 
 +
          <div class="p-5 rounded bg-primary">
 +
            <a href="#abstract" class="tongue tongue-bottom scroll-me"><i class="fas fa-angle-down"></i></a>
 +
          </div>
 +
 
 +
        </div>
 +
       </div>
 +
    </section>
 +
 
 +
 
 +
 
 +
    <section id="abstract" class="slice">
 +
      <div class="container">
 +
        <div class="mb-5 text-center">
 +
          <br>
 +
          <h3 class="heading h3"><font size="+5">This is CAPOEIRA</font></h2>
 +
        </div>
 +
 
 +
 
 +
        <div class="row row-grid align-items-center slice slice-lg">
 +
          <div class="col-lg-5">
 +
            <div class="animate-this">
 +
            <img src="https://static.igem.org/mediawiki/2018/0/01/T--EPFL--bioinfo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          </div>
 +
          <div class="col-lg-7 ml-lg-auto">
 +
            <div>
 +
              <h2 class="text-center"><font size="+2">Bioinformatics</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
        <br>
 +
        <div class="row row-grid align-items-center slice slice-lg">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/b/b2/T--EPFL--vaccine-logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"><font size="+2">Vaccine</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5">
 +
            <img src="https://static.igem.org/mediawiki/2018/4/4a/T--EPFL--DCentier.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 ml-lg-auto">
 +
            <div>
 +
              <h2 class="text-center"><font size="+2">Dendritic cell Activation</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells</font>
 +
              </p>
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
        <div class="row row-grid align-items-center">
 +
          <div class="col-lg-5 order-lg-2 ml-lg-auto">
 +
            <img src="https://static.igem.org/mediawiki/2018/3/3d/T--EPFL--follow_up_logo.svg" class="img-center img-fluid" width="300px">
 +
          </div>
 +
          <div class="col-lg-7 order-lg-1">
 +
            <div class="pr-lg-7">
 +
              <h2 class="text-center"> <font size="+2">Follow-up</font></h2>
 +
              <p class="lead text-gray my-4 text-center">
 +
                <font size="+2">Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA</font>
 +
              </p>
 +
 
 +
            </div>
 +
          </div>
 +
        </div>
 +
 
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 +
      </div>
 +
 
 +
 
 +
 
 +
      <section class="slice slice-xl bg-cover bg-size--cover" style="background-image: url('https://static.igem.org/mediawiki/2018/4/4f/T--EPFL--TeamPage.jpeg'); background-position: center top;">
 +
          <div class="container">
 +
              <div class="row justify-content-center">
 +
                  <div class="col-lg-9">
 +
                      <div class="text-center">
 +
                          <h2 class="heading h1 text-white"> </br> </br> </br> Won: <span>Gold Medal</span></br> Nominated for: <span>Best Therapeutic Project</span> and <span>Best Software</br></ul></ui></h2>
 +
                          <div class="btn-container mt-5">
 +
                              <a href="https://2018.igem.org/Team:EPFL/Awards" class="btn btn-white btn-primary btn-circle px-5">Our Awards!</a>
 +
                          </div>
 +
                      </div>
 +
                  </div>
 +
              </div>
 +
          </div>
 +
      </section>
 +
      <div class="container">
 +
 
 +
<hr style="height:2px;border:none;color:#333;background-color:#333;" >
 +
 
 +
      <div class="row">
 +
<video class="responsive-video center-margin" style="width: 100%; padding: 30px" controls>
 +
              <source src="https://static.igem.org/mediawiki/2018/7/77/T--EPFL--iGEM_2018_video.mp4" type="video/mp4" >
 +
              </video>
 +
      </div>
 +
 
 +
 
 
     </div>
 
     </div>
    <div class="col-sm-3">
 
      <a href="https://2018.igem.org/Team:EPFL/Description#Vaccine">
 
      <img src="https://static.igem.org/mediawiki/2018/9/93/T--EPFL--vaccine.png" class="img-circle project_part" alt="Vaccine" width="255" height="255"> <br>
 
      </a>
 
      <p><strong>Expression of the neoantigens and the adjuvant using encapsulin</strong></p>
 
    </div>
 
    <div class="col-sm-3">
 
      <a href="https://2018.igem.org/Team:EPFL/Description#Dendritic">
 
      <img src="https://static.igem.org/mediawiki/2018/1/1f/T--EPFL--Dendritic.png" class="img-circle project_part" alt="Dendritic" width="255" height="255"> <br>
 
      </a>
 
      <p><strong>Maturation of dendritic cells and T-cells</strong></p>
 
    </div>
 
    <div class="col-sm-3">
 
      <a href="https://2018.igem.org/Team:EPFL/Description#Followup">
 
      <img src="https://static.igem.org/mediawiki/2018/3/3c/T--EPFL--follow_up.png" class="img-circle project_part" alt="follow_up" width="255" height="255"> <br>
 
      </a>
 
      <p><strong>Detection of cancer relapse using liquid biopsies of ctDNA and cancer miRNA</strong></p>
 
    </div>
 
  </div>
 
  
  
 +
    </section>
 +
 +
  </main>
 
</body>
 
</body>
  
 
</html>
 
</html>
 +
{{EPFL/Footer}}

Latest revision as of 00:21, 8 December 2018

iGEM EPFL 2018

CAPOEIRA

CAncer PersOnalized Encapsulin Immunotherapy and Relapse Assay

Learn more about our project

What is CAPOEIRA ?

While Melanoma remains the deadliest form of skin cancer, immunotherapy approaches can harness our immune system to defeat it! Yet, current immuno-treatments suffer from high costs, limited accessibility, and poor specificity. Our project “CAPOEIRA”, named after the Brazilian self-defense martial-art, exploits the potential of synthetic biology to develop a personalized, cost-effective, and rapid production scheme for cancer vaccine and point-of-care relapse surveillance. First, a bioinformatic pipeline integrating state-of-the-art tools identifies our targets: melanoma neoantigens, the fingerprints of cancer cells. Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes. This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen-bearing cancer cells. Nevertheless, we don’t underestimate a defeated villain! To detect potential relapse, we combine techniques including dumbbell probes, rolling circle amplification, isothermal amplification, and CRISPR-Cas12a to detect circulating tumor miRNA and DNA. Ultimately, CAPOEIRA trains the immune system to fight back!


This is CAPOEIRA

Bioinformatics

First, a bioinformatic pipeline integrating state-of-the-art tools identifies our target: melonoma neoantigens, the fingerprints of cancer cells


Vaccine

Next, cell-free protein expression rapidly synthesizes a library of encapsulin protein nanocompartments presenting the various neoantigen epitopes

Dendritic cell Activation

This encapsulin vaccine activates dendritic cells which trigger a T-cell attack on the neoantigen bearing cancer cells

Follow-up

Nevertheless, we don't underestimate a defeated villain! To detect potential relapse we use techniques like CRISPR-Cas12a to detect circulationg tumor miRNA and DNA





Won: Gold Medal
Nominated for: Best Therapeutic Project and Best Software